Oxprenolol


Thông tin kê toa tóm tắt
Chỉ định/Công dụng
Listed in Dosage.
Liều dùng/Hướng dẫn sử dụng
Adult : PO HTN 80-160 mg/day in 2 or 3 divided doses. May increase dose 1-2 wkly. Max: 320 mg/day. Angina pectoris 80-160 mg/day in 2 or 3 divided doses. Max: 320 mg/day. Cardiac arrhythmias 40-240 mg/day in 2 or 3 divided doses. Anxiety 40-80 mg/day in 1 or 2 divided doses.
Dosage Details
Oral
Hypertension
Adult: 80-160 mg/day in 2 or 3 divided doses. May increase dose every 1-2 wk until adequate response is obtained. Max: 320 mg/day.

Oral
Angina pectoris
Adult: 80-160 mg/day in 2 or 3 divided doses. Max: 320 mg/day.

Oral
Cardiac arrhythmias
Adult: 40-240 mg/day in 2 or 3 divided doses.

Oral
Anxiety
Adult: 40-80 mg/day as a single dose or in 2 divided doses.
Cách dùng
May be taken with or without food.
Chống chỉ định
AV block (2nd and 3rd degree), bradycardia, uncontrolled heart failure, hypotension, history of bronchospasm or bronchial asthma, sick sinus syndrome, cardiogenic shock, severe peripheral arterial circulatory disturbances, Prinzmetal's angina, metabolic acidosis and use of anaesth.
Thận trọng
Chronic obstructive lung disease, 1st degree AV block, untreated CHF, peripheral vascular disease (e.g. Raynaud's syndrome). May mask symptoms of hypoglycaemia and hyperthyroidism. Hepatic and renal impairment. Abrupt withdrawal of treatment is not advisable in patients w/ ischaemic heart disease. Pregnancy and lactation.
Phản ứng phụ
Hypotension, heart failure, peripheral vascular disorders (e.g. cold extremities, paraesthesia). Fatigue, dizziness, headache, mental depression, disturbances in libido and potency. Dry mouth, constipation, nausea, dyspnoea, bronchoconstriction, skin rash.
Thông tin tư vấn bệnh nhân
May impair ability to drive or operate machinery.
Quá liều
Symptoms: Hypotension, bradycardia, CHF, bronchospasm, hypoglycaemia, cardiogenic shock, cardiac arrest, conduction abnormalities, dyspnoea, vomiting, impairment of consciousness and generalised convulsions. Rhabdomyolysis w/ myoglobinuria. Management: Perform gastric lavage and administer activated charcoal w/in 4 hr of ingestion. Initial treatment w/ atropine should be used for bradycardia. High dose isoprenaline may be needed to control heart rate and hypotension. Glucagon is a useful alternative treatment for hypotension and heart failure. For seizures, use diazepam. Administer aminophylline, salbutamol or terbutaline in case of bronchospasm.
Tương tác
May enhance effects of insulin and oral antidiabetics. Concurrent use w/ cimetidine may increase plasma levels and prolong half-life. May enhance the vasoconstrictive effects of ergot alkaloids. Potentiation of hypotension, bradycardia and myocardial depression may occur w/ Ca channel blockers (e.g. diltiazem, verapamil). May have additive cardiodepressant effect w/ anaesth (e.g. halothane). Enhanced pressor response to sympathomimetic drugs (e.g. epinephrine, phenylephrine, isoprenaline, noradrenaline). Concomitant admin w/ quinidine, amiodarone, disopyramide may induce negative inotropic effect and increase atrial-conduction time. May enhance lidocaine effects. Additive effect w/ reserpine, guanethidine. May enhance depressant effect w/ digitalis glycosides. Reduced hypotensive effect w/ NSAIDs.
Food Interaction
Additive effect w/ alcohol.
Tác dụng
Description: Oxprenolol is a non-cardioselective β-blocker. It competitively antagonises catecholamine-induced tachycardia at cardiac β-receptor sites, resulting in reduced cardiac output.
Pharmacokinetics:
Absorption: Well absorbed from the GI tract. Bioavailability: 20-70%. Time to peak plasma concentration: Approx 1 or 2 hr.
Distribution: Enters breast milk, crosses the placenta and blood-brain barrier. Plasma protein binding: Approx 80%.
Metabolism: Undergoes first-pass hepatic metabolism.
Excretion: Via urine. Elimination half-life: 1-2 hr.
Bảo quản
Store at 30°C. Protect from heat and moisture.
Phân loại MIMS
Thông báo miễn trừ trách nhiệm: Thông tin này được MIMS biên soạn một cách độc lập dựa trên thông tin của Oxprenolol từ nhiều nguồn tài liệu tham khảo và được cung cấp chỉ cho mục đích tham khảo. Việc sử dụng điều trị và thông tin kê toa có thể khác nhau giữa các quốc gia. Vui lòng tham khảo thông tin sản phẩm trong MIMS để biết thông tin kê toa cụ thể đã qua phê duyệt ở quốc gia đó. Mặc dù đã rất nỗ lực để đảm bảo nội dung được chính xác nhưng MIMS sẽ không chịu trách nhiệm hoặc nghĩa vụ pháp lý cho bất kỳ yêu cầu bồi thường hay thiệt hại nào phát sinh do việc sử dụng hoặc sử dụng sai các thông tin ở đây, về nội dung thông tin hoặc về sự thiếu sót thông tin, hoặc về thông tin khác. © 2020 MIMS. Bản quyền thuộc về MIMS. Phát triển bởi MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in